A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy (clinicaltrials.gov) - Oct 6, 2026 - P3 | N=540 | Recruiting | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Recruiting
Enrollment open • Glomerulonephritis • IgA Nephropathy • Renal Disease
|